In The Press:
Askeladden Advocates for Ability of Non-Defendant IPR Petitioners to Appeal Adverse PTAB Decisions
Patent Quality Initiative reports on amicus brief filed in support of JTEKT’s petition for rehearing en banc at the Federal Circuit Askeladden is represented by Amster Rothstein and Ebenstein LLP. Available Here.
ARE Patent Law Alert:SUPREME COURT TO CLARIFY ‘ON SALE’ BAR IN HELSINN HEALTHCARE S.A. V. TEVA PHARMS. USA, INC.
On June, 25, 2018, the U.S. Supreme Court granted certiorari in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., No. 17-1229 to address the scope of the “on-sale bar” after the Leahy-Smith America Invents Act (“AIA”). Specifically, the Court will consider whether confidential prior sales of an invention trigger the on-sale bar, and qualify as […]
In The Press: IPLaw360 Reports on Federal Circuit Asking Google to Respond to Petition for Rehearing and Rehearing En Banc
IP Law360, May 21, 2018 Fed. Circ. Asks Google Whether Full Court Should Eye Patents Law360 Reports on Federal Circuit Asking Google to Respond to Petition for Rehearing and Rehearing En Banc Law360 reported on The Federal Circuit on Friday asked Google to weigh in on a patent licensing company’s request for the entire court to review […]
In The Press:
Law360 Reports on NYIPLA Amicus Brief Submited to SCOTUS By Firm Regarding Standing of Disasstified Petitioners In An IPR To Appeal An Adverse Ruling
IP Law360, July 23, 2018 Law360 Reports on NYIPLA Amicus Brief Submited to SCOTUS By Firm Regarding Standing of Disasstified Petitioners In An IPR To Appeal An Adverse Ruling (July 23, 2018, Law360) Law 360 Reported on amicus brief filing on behalf of NYIPLA by Partner Charles R. Macedo (as counsel of record and […]
In The Press: Askeladden Advocates against Tribal Sovereign Immunity for Inter Partes Review Proceedings
Patent Quality Initiative reports on Amicus brief finding tribal sovereign immunity inapplicable to inter partes review (IPR) Askeladden is represented by Amster Rothstein and Ebenstein LLP. Available Here.
Patent Law Alert:In Oil States Energy Services, LLC v. Greene’s Energy Group, LLC, U.S. Supreme Court Held That Inter Partes Review by the Patent Trial and Appeal Board Does Not Violate Article III or the Seventh Amendment
On April 24, 2018, the United States Supreme Court issued its much-anticipated decision in Oil States Energy Servs., LLC v. Greene’s Energy Group, LLC, affirming the United States Court of Appeals for the Federal Circuit’s judgment that inter partes review does not violate Article III or the Seventh Amendment. This 7-2 majority opinion of the Court […]
In The Press: PTAB Finds N5 Technologies Patent to be Unpatentable Following Challenge from Askeladden
Askeladden successfully proves that all eleven claims of the mobile authentication patent were unpatentable. Askeladden is represented by Amster Rothstein and Ebenstein LLP. Available Here.
In The Press:
NYIPLA Participates in 2018 PTAB Judicial Conference in Alexandria, Virginia
On June 28, 2018, the USPTO hosted its 2018 PTAB Judicial Conference in Alexandria, Virginia. This was the first in a series of Judicial Conferences being hosted throughout the country. The NYIPLA was honored to participate in the conference with Charley Macedo, from Amster, Rothstein & Ebenstein LLP, co-chair of the newly created PTAB Committee […]
In The Press:Askeladden LLC Submits Another Amicus Brief Advocating Against Tribal Sovereign Immunity for PTAB Proceedings
IPWatchdog reports — Askeladden again submitted an amicus brief to the Federal Circuit on May 17, 2018 supporting the PTAB’s decision below. A copy of that amicus brief is available here. Askeladden is represented by Amster Rothstein and Ebenstein LLP.
ARE Patent Law Alert:“Diagnose and Treat†Claims Held Patentable By Federal Circuit – A Path Forward For Patentability
On April 13, 2018, a three-judge panel of the United States Court of Appeals for the Federal Circuit (CAFC), held in a 2-1 split decision in Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals, No. 2016-2707 & 2016-2708 that claims directed to a specified method of treatment based on a previously-performed, specified diagnosis are patentable. By way […]